Sulfoxide

Integra LifeSciences Announces Complete Enrollment in DuraSorb® Monofilament Mesh U.S. IDE Study

Retrieved on: 
Wednesday, June 28, 2023
Surgeon, PRS, Integra, Weakness, Woman, Trial of the century, Breast reconstruction, Police, PMA, SIA, Patient, IDE, Health, FDA, Safety, Breast cancer, Medical device, Medical imaging, Nursing, Sulfoxide, Brigham

PRINCETON, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq:IART), a leading global medical technology company, announced the completion of patient enrollment in the DuraSorb U.S. investigational device exemption (IDE) clinical study for two-stage breast reconstruction.

Key Points: 
  • PRINCETON, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq:IART), a leading global medical technology company, announced the completion of patient enrollment in the DuraSorb U.S. investigational device exemption (IDE) clinical study for two-stage breast reconstruction.
  • DuraSorb® Monofilament Mesh is a bioabsorbable matrix currently 510(K) cleared for the reinforcement of soft tissue where weakness exists.
  • The DuraSorb IDE study, which is the first and only active, prospective, multi-center IDE study in the U.S. evaluating the use of a surgical matrix in two-stage breast reconstruction, has enrolled several hundred patients from seven major academic hospitals across the country sooner than anticipated.
  • In addition to the ongoing DuraSorb U.S. IDE study, Integra was the first manufacturer to submit a PMA application with SurgiMend® PRS , a surgical matrix for use as soft tissue support in IBBR.

Integra LifeSciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance

Retrieved on: 
Wednesday, February 22, 2023
Public expenditure, EPS, Digital, OPEX, Organic, Investment, Goldman Sachs, Acquisition, EBITDA, Patient, TWC, Amniotic fluid, GAAP, Sulfoxide, Total, Completeness, Integra, Growth, Share repurchase, COVID-19, Cryptocurrency, Video game, Pharmaceutical industry, Bank, Security (finance), Management, Music, CUSA, Neurosurgery, Instrument

PRINCETON, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2022, consistent with its preliminary financial results announced on January 10, 2023 and January 25, 2023.

Key Points: 
  • PRINCETON, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2022, consistent with its preliminary financial results announced on January 10, 2023 and January 25, 2023.
  • Adjusted EBITDA for the fourth quarter of 2022 was $109.7 million, compared to $105.4 million in the fourth quarter of the prior year.
  • Adjusted net income for the fourth quarter of 2022 was $78.8 million, or $0.94 per diluted share, compared to adjusted net income of $72.2 million, or $0.84 per diluted share, in the fourth quarter of 2021.
  • ET on Wednesday, February 22, 2023, to discuss fourth quarter and full-year 2022 financial results, and forward-looking financial guidance.

Integra LifeSciences Announces Definitive Agreement to Acquire Surgical Innovation Associates (SIA) and Plans for $150 Million Share Repurchase

Retrieved on: 
Thursday, December 1, 2022
Growth, TCC, ICP, Sulfoxide, Merck KGaA v. Integra Lifesciences I, Ltd., Northwestern University, Safety, Acquisition, Health, Integra, BofA Securities, Annual report, Proskauer, PMA, Security (finance), News, Bank of America, Surgeon, Risk, Share repurchase, Woman, PRS, Breast cancer, Mastectomy, FDA, Medical imaging, Bank, Financial adviser, Risk management

PRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (NASDAQ:IART), a leading global medical technology company, today announced that it entered into a definitive agreement to acquire Surgical Innovation Associates (SIA), which develops, markets and sells DuraSorb®, a resorbable synthetic matrix for plastic and reconstructive surgery. This acquisition will advance Integra’s global strategy in breast reconstruction, expanding plans to access the U.S. market with devices specifically approved by the FDA for use in implant-based breast reconstruction (IBBR) procedures. The transaction is expected to close by the end of the year, subject to the satisfaction of customary conditions.

Key Points: 
  • The addition of DuraSorbs resorbable synthetic technology will further strengthen Integras plastic and reconstructive surgery portfolio, which includes SurgiMend PRS , a xenograft surgical matrix.
  • The global breast reconstruction market represents an attractive growth opportunity for our surgical reconstruction business, said Robert T. Davis, Jr., executive vice president and president, Tissue Technologies, Integra LifeSciences.
  • The company is planning a $150 million share repurchase as a part of a previous approval by the board of directors.
  • Surgical Innovation Associates, Inc (SIA) is a Northwestern University spin-out founded in 2016 by Alexei Mlodinow, Todd Cruikshank, and technology inventor Dr. John Kim.

Surgical Innovation Associates (SIA) Announces Definitive Agreement to be Acquired by Integra LifeSciences

Retrieved on: 
Thursday, December 1, 2022
Research, General Health, Oncology, Medical Devices, Other Manufacturing, Science, Surgery, Chemicals, Plastics, Biotechnology, Medical Supplies, Manufacturing, Health, Warning, Growth, TCC, Weakness, Use, ICP, Sulfoxide, Merck KGaA v. Integra Lifesciences I, Ltd., Northwestern University, Ideation, Acquisition, Health, Physician, Patient, Integra, BofA Securities, Proskauer, Federal Food, Drug, and Cosmetic Act, PMA, News, Bank of America, Surgeon, CE, Entrepreneurship, Mastectomy, PRS, FDA, Health insurance, Medical device, Medical imaging, EU

Surgical Innovation Associates (SIA) today announced that it entered into a definitive agreement to be acquired by Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company.

Key Points: 
  • Surgical Innovation Associates (SIA) today announced that it entered into a definitive agreement to be acquired by Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company.
  • The transaction is expected to close by the end of the year, subject to the satisfaction of customary conditions.
  • Today, there are no surgical matrices approved by the FDA specifically for use in implant-based breast reconstruction (IBBR) for mastectomy patients.
  • Integra is the only manufacturer so far to submit a premarket approval (PMA) application for this soft tissue support in IBBR.

Surgical Innovation Associates Raises $15 Million in Oversubscribed Series B Round, Appoints Veteran Medtech CEO

Retrieved on: 
Thursday, December 16, 2021
Biotechnology, Health, Surgery, Medical Devices, History of the Georgia Institute of Technology, Weakness, FDA, MIT, Central nervous system, Northwestern Memorial Hospital, MIT Sloan School of Management, Beth Israel Deaconess Medical Center, PHP, Chemical engineering, S.A, Growth, III, Wound healing, Medtronic, Medical college, Acquisition, General surgery, LLC, Pharmacokinetics, Baxter International, CEO, Sulfoxide, Leadership, Health care, CE, BS, Federal Food, Drug, and Cosmetic Act, Pioneer, Surgeon, MBA, Use, MD, Warning, Ideation, Medical College of Georgia, Technology, PEAK, 3D printing, Pharmaceutical industry, Medical device, Management, EU, LP, Allergan, Surgical Innovation Associates (SIA), Pioneer Healthcare Partners, LP, SURGICAL INNOVATION ASSOCIATES (SIA), PIONEER HEALTHCARE PARTNERS, LP

Pioneer Healthcare Partners, LP, led the $15 Million financing, which was oversubscribed.

Key Points: 
  • Pioneer Healthcare Partners, LP, led the $15 Million financing, which was oversubscribed.
  • Participants included both new and existing investors, as well as current board members, who have collectively infused more than $20 million since the companys founding in 2016.
  • Dr. Mlodinow, the founding CEO of SIA, began his plastic and reconstructive surgery residency at Northwestern Memorial Hospital in June, 2021.
  • This Series B round sets the stage for us to expand our efforts to raise the standard of care in surgery.

Global Methylsulfonylmethane Market Report 2021-2029: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021
Retail, Chemicals, Plastics, Manufacturing, Food, Beverage, Chemistry, Physical sciences, Natural sciences, Solvents, Functional groups, Sulfones, Methylsulfonylmethane, Sulfone, Dimethyl sulfoxide, Sulfoxide, MSM, Sulfur

The "Methylsulfonylmethane Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Methylsulfonylmethane Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Methylsulfonylmethane (MSM) is a form of organic sulfur that is found in many different fruits, vegetables, grains, and animals.
  • Methylsulfonylmethane is a product of dimethyl sulfoxide (DMSO) and is also known as DMSO2, methyl sulfone, and dimethyl sulfone.
  • The methylsulfonylmethane market of Asia Pacific zone is predicted to register highest rate of growth during the projected period.

Global Dimethyl Sulfoxide Market Analysis, Trends, and Forecasts 2019-2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 27, 2019
Professional services, Consulting, Solvents, Dimethyl sulfoxide, Sulfoxides, Sulfoxide

The "Dimethyl Sulfoxide (DMSO) - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dimethyl Sulfoxide (DMSO) - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The Dimethyl Sulfoxide (DMSO) market worldwide is projected to grow by US$83.1 Million, driven by a compounded growth of 5.8%.
  • Poised to reach over US$150.4 Million by the year 2025, Pharmaceutical will bring in healthy gains adding significant momentum to global growth.
  • Competitors identified in this market include:
    Hubei Xingfa Chemicals Group Co., Ltd.
    Yangmei Fengxi Fertilizer Industry (Group) Co., Ltd.

Global Dimethyl Sulfoxide (DMSO) Industry

Retrieved on: 
Wednesday, October 16, 2019
Dimethyl sulfoxide, Solvents, Sulfoxides, Sulfoxide

US Dimethyl Sulfoxide (DMSO) Market Share (in %) by Company:

Key Points: 
  • US Dimethyl Sulfoxide (DMSO) Market Share (in %) by Company:
    Forecasts in US$ by Application: 2018 to 2025
    the United States by Application: 2009 VS 2019 VS 2025
    Quantitative Demand Analysis in US$ by Application: 2018 to
    Table 17: Dimethyl Sulfoxide (DMSO) Market in Canada:
    Sulfoxide (DMSO) in US$ by Application: 2018 to 2025
    European Dimethyl Sulfoxide (DMSO) Market: Competitor Market
    Scenario in US$ by Region/Country: 2018-2025
    Table 26: Dimethyl Sulfoxide (DMSO) Market in Europe: A
    Opportunity in US$ by Application: 2018-2025
    Table 29: Dimethyl Sulfoxide (DMSO) Market in Europe:
    Analysis in France in US$ by Application: 2018-2025
    Review in US$ by Application: 2009-2017
    Analysis: A 17-Year Perspective by Application for 2009, 2019,
    Table 34: Dimethyl Sulfoxide (DMSO) Market in Germany: Annual
    Dimethyl Sulfoxide (DMSO) in US$ by Application: 2018 to 2025
    Demand Analysis in US$ by Application: 2018 to 2025
    Table 44: Dimethyl Sulfoxide (DMSO) Market in Spain:
    Forecasts in US$ by Application: 2018 to 2025
    Market Opportunity in US$ by Application: 2018-2025
    Table 50: Dimethyl Sulfoxide (DMSO) Market in Rest of Europe:
    Estimates and Forecasts in US$ by Region/Country: 2018-2025
    Table 53: Dimethyl Sulfoxide (DMSO) Market in Asia-Pacific:
    Analysis in Asia-Pacific in US$ by Application: 2018-2025
    Market Review in US$ by Application: 2009-2017
    Analysis: A 17-Year Perspective by Application for 2009, 2019,
    Table 58: Dimethyl Sulfoxide (DMSO) Market in Australia: Annual
    Retrospect in US$ by Application: 2009-2017
    Demand Analysis in US$ by Application: 2018 to 2025
    Table 62: Dimethyl Sulfoxide (DMSO) Market in India:
    Table 64: Dimethyl Sulfoxide (DMSO) Market in South Korea:
    Market Analysis in US$ by Application: 2009-2017
    in South Korea by Application: 2009 VS 2019 VS 2025
    for Dimethyl Sulfoxide (DMSO) in US$ by Application: 2018 to
    Percentage Breakdown of Sales by Region/Country: 2009, 2019,
    America in US$ by Application: 2009-2017
    Market Opportunity in US$ by Application: 2018-2025
    Table 77: Dimethyl Sulfoxide (DMSO) Market in Argentina:
    Analysis in Brazil in US$ by Application: 2018-2025
    Review in US$ by Application: 2009-2017
    Analysis: A 17-Year Perspective by Application for 2009, 2019,
    Table 82: Dimethyl Sulfoxide (DMSO) Market in Mexico: Annual
    Retrospect in US$ by Application: 2009-2017
    Latent Demand Forecasts in US$ by Application: 2018 to 2025
    Rest of Latin America by Application: 2009 VS 2019 VS 2025
    Estimates and Forecasts in US$ by Region/Country: 2018-2025
    Quantitative Demand Analysis in US$ by Application: 2018 to
    Table 92: Dimethyl Sulfoxide (DMSO) Market in the Middle East:
    Sulfoxide (DMSO) in US$ by Application: 2018 to 2025
    Opportunity in US$ by Application: 2018-2025
    Table 98: Dimethyl Sulfoxide (DMSO) Market in Israel:
    Arabia in US$ by Application: 2009-2017
    Historic Market Analysis in US$ by Application: 2009-2017
    in United Arab Emirates by Application: 2009 VS 2019 VS 2025
    in Retrospect in US$ by Application: 2009-2017
    in Rest of Middle East by Application: 2009 VS 2019 VS 2025
    Forecasts in US$ by Application: 2018 to 2025